rhNRG-1
Phase 3Small molecule
rhNRG-1 is one of 37 small molecule programs targeting Heart Failure. It is currently in Phase 3.
2
Indications
7
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1rhNRG-1
ZZensun Sci. & Tech. Co., Ltd.
Phase 3
Bayer Aspirin
BayerPreclinical
Medrol
PfizerPreclinical
Activase
RochePreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhNRG-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZensun Sci. & Tech. Co., Ltd.